Sacituzumab govitecan
About
Therapy type: Targeted therapy
Therapy strategy: Topoisomerase inhibition
Mappings
NCI Thesaurus: Sacituzumab Govitecan (coding:ncit:C102783)
RxNorm: sacituzumab govitecan (coding:rxcui:2360232, coding:omop:1145485)
SNOMED: Sacituzumab govitecan (coding:sctid:871701001, coding:omop:3667004)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| FDA (1) HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| FDA (1) HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| FDA (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan |